Ascendo Biotechnology
Taipei, Taiwan· Est.
Taiwan biotech pioneering innate immune checkpoint inhibitors for oncology and autoimmunity.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwan biotech pioneering innate immune checkpoint inhibitors for oncology and autoimmunity.
OncologyImmunology
Technology Platform
Innate immune checkpoint modulation targeting the TLT‑1/CD11b axis to re‑activate myeloid cells and remodel the tumor microenvironment or immune balance.
Opportunities
Successful Phase I data could enable combination trials with anti‑PD‑1/CTLA‑4 and attract strategic partnerships, expanding market reach in resistant oncology and autoimmune indications.
Risk Factors
Limited funding visibility, small team size, and reliance on a single lead asset increase execution and de‑risking challenges.
Competitive Landscape
Few companies target innate immune checkpoints; Ascendo’s TLT‑1/CD11b approach offers a differentiated mechanism compared with conventional adaptive‑immune checkpoint inhibitors.